Although FGF21 is considered as a therapeutic target in obesity-related metabolic disorders, the potential of FGF21 to control the atrophy of skeletal muscle in obese conditions is unclear. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.